120 related articles for article (PubMed ID: 25963688)
1. [Progress in second-line therapies for metastatic breast cancer].
Shigekawa T; Osaki A; Saeki T
Gan To Kagaku Ryoho; 2015 Apr; 42(4):408-15. PubMed ID: 25963688
[TBL] [Abstract][Full Text] [Related]
2. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.
Carey LA; Dees EC; Sawyer L; Gatti L; Moore DT; Collichio F; Ollila DW; Sartor CI; Graham ML; Perou CM
Clin Cancer Res; 2007 Apr; 13(8):2329-34. PubMed ID: 17438091
[TBL] [Abstract][Full Text] [Related]
3. New developments in metastatic breast cancer: integrating recent data into clinical practice.
Perez EA; Rugo HS; Vahdat LT
Clin Adv Hematol Oncol; 2013; 11(10 Suppl 16):1-18; quiz 19. PubMed ID: 24892840
[TBL] [Abstract][Full Text] [Related]
4. Bevacizumab for the first-line treatment of human epidermal growth factor receptor 2-negative advanced breast cancer.
Damasceno M
Curr Opin Oncol; 2011 Apr; 23 Suppl():S3-9. PubMed ID: 21490481
[TBL] [Abstract][Full Text] [Related]
5. Is triple negative a prognostic factor in breast cancer?
Nishimura R; Arima N
Breast Cancer; 2008; 15(4):303-8. PubMed ID: 18369692
[TBL] [Abstract][Full Text] [Related]
6. Importance of confirming HER2 overexpression of recurrence lesion in breast cancer patients.
Nakamura R; Yamamoto N; Onai Y; Watanabe Y; Kawana H; Miyazaki M
Breast Cancer; 2013 Oct; 20(4):336-41. PubMed ID: 22367960
[TBL] [Abstract][Full Text] [Related]
7. Discordant human epidermal growth factor receptor 2 and hormone receptor status in primary and metastatic breast cancer and response to trastuzumab.
Chang HJ; Han SW; Oh DY; Im SA; Jeon YK; Park IA; Han W; Noh DY; Bang YJ; Kim TY
Jpn J Clin Oncol; 2011 May; 41(5):593-9. PubMed ID: 21406492
[TBL] [Abstract][Full Text] [Related]
8. Metastatic breast cancer: therapeutic options according to molecular subtypes and prior adjuvant therapy.
Guarneri V; Conte P
Oncologist; 2009 Jul; 14(7):645-56. PubMed ID: 19608638
[TBL] [Abstract][Full Text] [Related]
9. Beyond cytotoxic chemotherapy for the first-line treatment of HER2-negative, hormone-insensitive metastatic breast cancer: current status and future opportunities.
Conlin AK; Seidman AD
Clin Breast Cancer; 2008 Jun; 8(3):215-23. PubMed ID: 18650151
[TBL] [Abstract][Full Text] [Related]
10. Differential response of triple-negative breast cancer to a docetaxel and carboplatin-based neoadjuvant treatment.
Chang HR; Glaspy J; Allison MA; Kass FC; Elashoff R; Chung DU; Gornbein J
Cancer; 2010 Sep; 116(18):4227-37. PubMed ID: 20549829
[TBL] [Abstract][Full Text] [Related]
11. Progression and treatment of HER2-positive breast cancer.
Davoli A; Hocevar BA; Brown TL
Cancer Chemother Pharmacol; 2010 Mar; 65(4):611-23. PubMed ID: 20087739
[TBL] [Abstract][Full Text] [Related]
12. [Effective therapeutic regimens for patients with triple-negative (ER/PgR/HER2-negative) metastatic breast cancer].
Kan N; Kuwata K; Mise K; Kodama H
Gan To Kagaku Ryoho; 2010 Jul; 37(7):1259-64. PubMed ID: 20647706
[TBL] [Abstract][Full Text] [Related]
13. Defining the optimal sequence for the systemic treatment of metastatic breast cancer.
Mestres JA; iMolins AB; Martínez LC; López-Muñiz JI; Gil EC; de Juan Ferré A; Del Barco Berrón S; Pérez YF; Mata JG; Palomo AG; Gregori JG; Pardo PG; Mañas JJ; Hernández AL; de Dueñas EM; Jáñez NM; Murillo SM; Bofill JS; Auñón PZ; Sanchez-Rovira P
Clin Transl Oncol; 2017 Feb; 19(2):149-161. PubMed ID: 27314861
[TBL] [Abstract][Full Text] [Related]
14. Implications of different CA 15-3 levels according to breast cancer subtype at initial diagnosis of recurrent or metastatic breast cancer.
Park S; Ahn HK; Park LC; Hwang DW; Ji JH; Maeng CH; Cho SH; Lee JY; Park KT; Ahn JS; Park YH; Im YH
Oncology; 2012; 82(3):180-7. PubMed ID: 22433564
[TBL] [Abstract][Full Text] [Related]
15. Analysis of the pathologic response to primary chemotherapy in patients with locally advanced breast cancer grouped according to estrogen receptor, progesterone receptor, and HER2 status.
Fernández-Morales LA; Seguí MA; Andreu X; Dalmau E; Sáez A; Pericay C; Santos C; Montesinos J; Gallardo E; Arcusa A; Saigí E
Clin Breast Cancer; 2007 Apr; 7(7):559-64. PubMed ID: 17509165
[TBL] [Abstract][Full Text] [Related]
16. Evolving nonendocrine therapeutic options for metastatic breast cancer: how adjuvant chemotherapy influences treatment.
Conte P; Guarneri V; Bengala C
Clin Breast Cancer; 2007 Dec; 7(11):841-9. PubMed ID: 18269773
[TBL] [Abstract][Full Text] [Related]
17. Quantitative ER and PgR assessment as predictors of benefit from lapatinib in postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer.
Finn RS; Press MF; Dering J; O'Rourke L; Florance A; Ellis C; Martin AM; Johnston S
Clin Cancer Res; 2014 Feb; 20(3):736-43. PubMed ID: 24198242
[TBL] [Abstract][Full Text] [Related]
18. Long-term follow-up of patients with metastatic breast cancer: results of a retrospective, single-center analysis from 2000 to 2005.
Geiger S; Cnossen JA; Horster S; DiGioia D; Heinemann V; Stemmler HJ
Anticancer Drugs; 2011 Oct; 22(9):933-9. PubMed ID: 21666437
[TBL] [Abstract][Full Text] [Related]
19. First-line chemotherapy for metastatic breast cancer.
Telli ML; Carlson RW
Clin Breast Cancer; 2009 Jun; 9 Suppl 2():S66-72. PubMed ID: 19596645
[TBL] [Abstract][Full Text] [Related]
20. First-line endocrine therapy alone could be a reasonable treatment option for hormone-positive, HER2-positive metastatic breast cancer.
Peron J; Tredan O; Ray-Coquard I; Bachelot T; Labidi Galy SI; Favier B; Treilleux I; Guastalla JP
Bull Cancer; 2012 Feb; 99(2):E18-25. PubMed ID: 22257781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
